The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
Article Figures & Tables
Figures
- FIG. 1.
Plasma insulin concentrations during the two-step hyperinsulinemic-euglycemic clamp before (□) and after (⧫) rosiglitazone.
- FIG. 2.
Effects of 3 months of rosiglitazone treatment on insulin suppression of peripheral adipocyte lipolysis during the two-step hyperinsulinemic-euglycemic clamp.
- FIG. 3.
Effects of 3 months of rosiglitazone treatment on hepatic triglyceride, IMLC, and EMLC content. ▪, before rosiglitazone; [cjs2113], after rosiglitazone.
Tables
- TABLE 1
Anthropometric and fasting plasma metabolite concentrations before and after 3 months of rosiglitazone treatment
Before After P Body weight (kg) 92.3 ± 6.2 93.9 ± 5.7 0.34 BMI (kg/m2) 31.1 ± 1.6 31.9 ± 1.7 0.20 Lean body mass (kg) 61.3 ± 3.4 59.9 ± 2.5 0.98 Body fat (%) 29.9 ± 3.6 33.1 ± 4.5 0.78 HbA1c (%) 6.7 ± 0.4% 7.2 ± 0.6% 0.23 Plasma glucose (mmol/l) 9.0 ± 0.9 7.9 ± 0.9 0.02 Insulin (pmol/l) 93.6 ± 13.8 71.4 ± 7.8 0.03 C-peptide (pmol/l) 0.83 ± 0.08 0.76 ± 0.06 0.19 Glucagon (ng/l) 87.0 ± 9.0 83.2 ± 7.3 0.54 Total cholesterol (mmol/l) 4.97 ± 0.39 5.43 ± 0.41 0.09 HDL cholesterol (mmol/l) 0.88 ± 0.05 0.96 ± 0.05 0.15 LDL cholesterol (mmol/l) 2.92 ± 0.34 3.31 ± 0.21 0.14 Triglycerides (mmol/l) 6.31 ± 1.66 6.26 ± 1.34 0.97 Fatty acids (μmol/l) 497 ± 64 352 ± 55 0.003 Leptin (ng/ml) 21.1 ± 5.7 18.4 ± 4.7 0.34 Alkaline phosphatase (units/l) 72 ± 7 61 ± 7 0.007 γ-Glutamyl transpeptidase (units/l) 29 ± 6 17 ± 3 0.001 -
Data are means ± SE.
-
- TABLE 2
Rates of glucose and lipid oxidation before and after rosiglitazone therapy
Before rosiglitazone After rosiglitazone P Glucose oxidation Basal 32.4 ± 2.3 38.0 ± 5.0 0.24 Low-dose clamp 38.0 ± 2.9 46.6 ± 3.2 0.11 High-dose clamp 71.6 ± 4.7 73.5 ± 3.6 0.68 Lipid oxidation Basal 158.5 ± 8.8 149.7 ± 17.3 0.24 Low-dose clamp 138.9 ± 12.4 122.1 ± 8.9 0.33 High-dose clamp 67.7 ± 13.7 71.1 ± 13.1 0.59 -
Data are means ± SE.
-
In this Issue
March 2002, 51(3)
The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
